Search results
Massive study identifies new biomarkers for renal cancer subtypes, improving diagnosis...
Medical Xpress· 2 hours agoThe findings lay the groundwork to identify therapeutic targets in non-clear-cell renal cell carcinomas. Renal < ...
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients - British...
Nature· 3 days agoTregs trafficking is controlled by CXCR4. In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in ...
Good to Know: Grim diagnosis spurs Kent couple to sell possessions, plan RV trip of a lifetime
Akron Beacon Journal via Yahoo News· 9 hours agoBut a scan last summer found new growth and Dailey had surgery to remove tumors on the kidney. And...
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks· 14 hours agoIovance has two marketed products in its portfolio — Amtagvi (lifileucel) and Proleukin (aldesleukin). While the FDA recently approved Amtagvi under the accelerated pathway to treat advanced ...
Afinitor interactions: Other medications, alcohol, and more
Medical News Today· 3 days agoAfinitor has interactions with some other drugs and certain supplements. Before you start treatment...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 4 days agoModerna detailed plans for its individual neoantigen cancer vaccine in a first-quarter earnings...
Fighting Cancer: A Basic Guide To Checkpoint Inhibitors
Forbes· 14 hours agoThis article is part of an ongoing series on novel cancer advances, including immunotherapies such...
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 days agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks via Yahoo Finance· 4 days agoModerna/Merck also started two separate mid-stage studies in renal cell carcinoma and...
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
Zacks via Yahoo Finance· 5 days agoCabometyx (cabozantinib) generated revenues of $376.4 million, which missed the Zacks Consensus...